Charles M Rudin MD PhD

Oncology•New York, NY

Hematologic Oncology, Thoracic Cancer

Chief, Thoracic Oncology, Memorial Sloan Kettering Cancer Center

Request Appointment

530 East 74th StreetNew York, NY 10021
Book by Phone+1(231) 508-9647

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1995 - 1998
University of ChicagoResidency, Internal Medicine, 1993 - 1995
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1993

Certifications & Licensure

FL State Medical License 2022 - Present
NY State Medical License 2013 - 2027
NJ State Medical License 2018 - 2025
MD State Medical License 2003 - 2013
IL State Medical License 1993 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 2010

Clinical Trials

Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer Start of enrollment: 2000 Apr 01
Completed
Phase 1, Phase 2
Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2001 Apr 01
Completed
Phase 1
Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors Start of enrollment: 2001 Mar 01
Completed
Phase 1
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2003 Apr 01
Completed
Phase 1, Phase 2
Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery Start of enrollment: 2004 Aug 01
Completed
Phase 2
Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2004 Nov 01
Completed
Phase 2
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2007 Apr 01
Completed
Phase 1
Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment Start of enrollment: 2006 Sep 01
Completed
Phase 2
Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Completed
Phase 2
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 Start of enrollment: 2019 Dec 11
RECRUITING
Roles: Contact
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer Start of enrollment: 2019 Mar 15
TERMINATED
PHASE1, PHASE2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Tumor-Infiltrating Clonal Hematopoiesis.
Oriol Pich, Elsa Bernard, Maria Zagorulya, Andrew Rowan, Constandina Pospori
The New England Journal of Medicine. 2025-04-24
1 citations
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-03-01
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors.
Susan C Scott, Anna Farago, W Victoria Lai, Marianna Zahurak, Michelle A Rudek
Cancer Chemotherapy and Pharmacology. 2025-02-25

Journal Articles

PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung Cancers
G J Riely, J Dienstag, C Mrad, J K Sabari, M G Kris, K C Arbour, D F Halpenny, N Rekhtman, R Chen, A J Plodkowski, P K Paik, B T Li, I Bergagnini, M D Offin, C M Rudin..., Annals of Oncology

Other

Head and neck squamous cell carcinogenesis: Molecular and genetic alterations
Rudin CM, Marur S
http://www.uptodate.com/contents/head-and-neck-squamous-cell-carcinogenesis-molecular-and-genetic-al
UpToDate, Wolters Kluwer Health - 2012-04-09
Chemoprevention in oral dysplasia and head and neck cancer
Rudin CM, Marur S
http://www.uptodate.com/contents/chemoprevention-in-oral-dysplasia-and-head-and-neck-cancer
UpToDate, Wolters Kluwer Health - 2012-05-31

Press Mentions

Novel TKI Highly Active in HER2-Mutant Lung CancerApril 29th, 2025
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024February 27th, 2025
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024October 24th, 2024
Join now to see all

Grant Support

Novel therapeutic development for small cell lung cancerSLOAN-KETTERING INST CAN RESEARCH2021–2028
Coordinating center for the NCI small cell lung cancer research consortiumSLOAN-KETTERING INST CAN RESEARCH2022–2027
Drivers of histologic transformation in EGFR-mutant lung cancerSLOAN-KETTERING INST CAN RESEARCH2021–2026
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science CenterEMORY UNIVERSITY2019–2025

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS North Carolina BlueOptions PPO
Blue Shield California PPO
CareFirst BCBS Maryland POS
CareFirst BlueChoice Advantage
CareFirst BlueChoice Network POS
CareFirst BluePreferred PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment

Charles M Rudin MD PhD

Overview of Dr. Rudin

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Insurance Accepted

Viewing the full profile is available to verified healthcare professionals only.